scholarly journals Optimal surgical treatment for paratesticular leiomyosarcoma: retrospective analysis of 217 reported cases

BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Rei Kamitani ◽  
Kazuhiro Matsumoto ◽  
Toshikazu Takeda ◽  
Ryuichi Mizuno ◽  
Mototsugu Oya
Keyword(s):  
Prognostic Factors ◽  
Treatment Strategy ◽  
Optimal Treatment ◽  
The Other ◽  
Free Survival ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Grade 3 ◽  
Disease Specific ◽  
Optimal Treatment Strategy

Abstract Background Paratesticular leiomyosarcoma (LMS) is a rare tumor. Conventionally, tumor resection by high inguinal orchiectomy is performed as the preferred treatment approach for paratesticular sarcoma. On the other hand, testis-sparing surgery has recently attracted attention as a less-invasive treatment option for paratesticular sarcoma. However, the prognostic predictors and optimal treatment strategy for paratesticular LMS remain unclear because of its rarity. In this study, we systematically reviewed previously reported cases of paratesticular LMS to evaluate the prognostic factors and establish the optimal treatment strategy. Methods A systematic search of Medline, Web of Science, Embase, and Google was performed to find articles describing localized paratesticular LMS published between 1971 and 2020 in English. The final cohort included 217 patients in 167 articles. The starting point of this study was the time of definitive surgical treatment, and the end point was the time of local recurrence (LR), distant metastasis (DM), and disease-specific mortality. Results Patients with cutaneous LMS had a slightly better LR-free survival, DM-free survival, and disease-specific survival than those with subcutaneous LMS (p = 0.745, p = 0.033, and p = 0.126, respectively). Patients with higher grade tumors had a significantly higher risk of DM and disease-specific mortality (Grade 3 vs Grade 1 p < 0.001, and Grade 3 vs Grade 1 p < 0.001, respectively). In addition, those with a microscopic positive margin had a significantly higher risk of LR and DM than those with a negative margin (p < 0.001, and p = 0.018, respectively). Patients who underwent simple tumorectomy had a slightly higher risk of LR than those who underwent high inguinal orchiectomy (p = 0.067). Subgroup analysis of cutaneous LMS demonstrated that the difference in LR between simple tumorectomy and high inguinal orchiectomy was limited (p = 0.212). On the other hand, subgroup analysis of subcutaneous LMS revealed a significant difference in LR (p = 0.039). Conclusions Our study demonstrated that subcutaneous LMS and high-grade tumors are prognostic factors for paratesticular LMS. For subcutaneous LMS, tumorectomy with high inguinal orchiectomy should be the optimal treatment strategy to achieve a negative surgical margin.

scholarly journals Epithelioid hemangioendothelioma of bone: A survival analysis of 50 cases from the SEER database (1992–2016)

Rare Tumors ◽  
2021 ◽  
Vol 13 ◽  
pp. 203636132110055
Author(s):  
Charles A Gusho ◽  
Sarah C Tepper ◽  
Steven Gitelis ◽  
Alan T Blank
Keyword(s):  
Prognostic Factors ◽  
Cox Regression ◽  
Axial Skeleton ◽  
Epithelioid Hemangioendothelioma ◽  
Appendicular Skeleton ◽  
Seer Database ◽  
Large Patient ◽  
Specific Mortality ◽  
Disease Specific Mortality ◽  
Disease Specific

Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor that may arise in bone. The purpose of this investigation was to determine the clinicopathological features and outcomes of osseous EHE in a large patient series, and to assess whether survival is impacted by demographics, tumor characteristics, or treatment factors. This was a retrospective review of the Surveillance, Epidemiology and End Results (SEER) database from 1992 to 2016. Kaplan-Meier was used to estimate overall survival (OS) and disease-specific survival (DSS). A Cox regression model was used to identify prognostic factors. Fifty patients from 1992 to 2016 with a median age of 54.5 years (IQR, 37–67) were reviewed. For location, 46% ( n = 23) of tumors arose from the appendicular skeleton while 38% ( n = 19) occurred within the axial skeleton (overlapping EHE: 16%, n = 8). Of the cases with recorded treatment factors, 54.8% ( n = 23) had surgery, 26% ( n = 13) received radiation, 22% ( n = 11) were treated with chemotherapy, and 26% ( n = 13) had surgery plus radiation. The 5-year OS probability was 49.2% (95% CI, 23.6–70.6), and the 5-year DSS probability was 63.9% (95% CI, 33.0–83.5). No surgery (surgery: HR, 0.262; 95% CI, 0.07–0.9); p = 0.041) and age older than 50 years (HR, 4.117; 95% CI, 1.1–15.4; p = 0.035) were negative prognostic factors of disease-specific mortality after controlling for confounding variables. There was no association between disease-specific mortality and adjuvant or multimodal therapy. The prognosis of EHE of bone is less than favorable, and the 5-year DSS probability of 64% emphasizes the intermediate grade nature of this tumor subtype. Surgical treatment, when feasible, is associated with a better prognosis.

Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 502-502 ◽  
Author(s):  
R. S. Punglia ◽  
E. P. Winer ◽  
J. C. Weeks ◽  
H. J. Burstein
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitors ◽  
Treatment Strategy ◽  
Early Stage ◽  
Disease Free Survival ◽  
Optimal Treatment ◽  
Endocrine Treatment ◽  
Free Survival ◽  
Disease Free ◽  
Optimal Treatment Strategy

502 Background: Adjuvant endocrine treatment with upfront aromatase inhibitors yields improved disease-free survival compared to tamoxifen in unselected women with estrogen receptor-positive breast cancer. However, levels of endoxifen, the active tamoxifen metabolite, are known to vary with the number of mutant alleles of the cytochrome P450 CYP2D6 enzyme. We created a Markov model to examine whether the optimal treatment strategy for patients with wild type genetics (wt/wt) might differ from that for patients with homozygous (*4/*4) or heterozygous (wt/*4) mutations. Methods: Annual recurrence risks with aromatase inhibitors and tamoxifen in unselected women were taken from the BIG 1–98 trial. Based on data from Goetz et al., we assumed that the percent of patients who are homozygous and heterozygous for mutations are 6.8% and 21.1%, respectively, and that the hazard ratio (HR) for increased cancer recurrence on tamoxifen among *4/*4 carriers is 1.86 relative to patients with wt/wt or wt/*4 genotypes. Because the efficacy of tamoxifen among wt/*4 patients is not known, we tested the full possible range, from efficacy same as wt/wt patients (Ehet=0) to that of *4/*4 mutation carriers (Ehet=1). Results: In the unselected group, 5-year disease-free survival (5-DFS) with aromatase inhibitors and tamoxifen was 0.840 and 0.813, respectively. Under baseline assumptions, tamoxifen is more effective than aromatase inhibitors among wt/wt patients as long as the effect in heterozygotes is at least 54% (Ehet=0.54) of that in *4/*4 patients. With increasing HR for *4/*4 patients, tamoxifen estimates exceed those of aromatase inhibitors in the wt/wt cohort even at lower assumed Ehet ratios (see table ). Conclusion: In patients without CYP2D6 mutations, modeling suggests that initial treatment with tamoxifen could be superior to treatment with aromatase inhibitors, supporting the use of genetic testing to determine the optimal treatment strategy. [Table: see text] No significant financial relationships to disclose.

Evidence-based optimal treatment strategy of patients with angina pectoris

2008 ◽  
Vol 149 (7) ◽  
pp. 293-298
Author(s):  
András Jánosi
Keyword(s):  
Angina Pectoris ◽  
Treatment Strategy ◽  
Optimal Treatment ◽  
Evidence Based ◽  
Optimal Treatment Strategy

A szerző összefoglalja a stabil angina pectoris optimális kezelésével kapcsolatos evidenciákat. Az invazív kezelési stratégia (katéterterápia) térnyerése a stabil angina pectoris esetében is megfigyelhető. Számos országban – így hazánkban is – a percutan intervenciók száma meghaladja a műtéti beavatkozások gyakoriságát. A percutan intervenció, illetve a revascularisatiós műtét helyének meghatározása az angina pectoris kezelésében igen fontos és sokszor vitatott klinikai probléma. A szerző áttekinti a lehetséges három kezelési mód (gyógyszeres kezelés, percutan intervenció, revascularisatiós műtét) eredményességét vizsgáló randomizált tanulmányokat, illetve az ezekből levonható következtetéseket. A rendelkezésre álló adatok azt igazolják, hogy – a diagnózis objektív módszerrel is alátámasztott felállítása után első lépésben – a rizikófaktorok korrekciója, az életmódrendezés és az optimális gyógyszeres kezelés a választandó kezelési stratégia. Optimális gyógyszeres kezelésnek tekintjük a statin-, aszpirin-, ACE-gátló-terápiát és a tünetek befolyásolására irányuló antianginás kezelést, amelyben a béta-blokkoló alkalmazásának elsőrendű jelentősége van. A percutan intervenció első terápiás eszközként történő alkalmazása nem indokolt, mivel nincs adat arra, hogy javítaná az életkilátásokat, illetőleg a beavatkozással megelőzhető lenne a szívinfarktus. Amennyiben a panaszok gyógyszeres kezeléssel nem vagy nem eléggé befolyásolhatók, indokolt a revascularisatio (percutan intervenció vagy műtét) elvégzése, mivel e beavatkozásokkal a gyógyszeres kezelésnél jobban javítható a funkcionális stádium. A revascularisatiós műtét bizonyos esetekben (pl. főtörzsszűkület, háromérbetegség és csökkent balkamra-funkció) a panaszok kedvező befolyásolásán túlmenően a betegek életkilátásait is javítja. A rendelkezésre álló kezelési lehetőségek optimális megválasztása nemcsak a betegek számára fontos, hanem komoly gazdasági jelentősége is van.

scholarly journals Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Fuqun Wei ◽  
Qizhen Huang ◽  
Yang Zhou ◽  
Liuping Luo ◽  
Yongyi Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Repeat Hepatectomy ◽  
Free Survival ◽  
Recurrent Hepatocellular Carcinoma ◽  
Primary Endpoints ◽  
Grade 3 ◽  
Optimal Treatment Strategy ◽  
Hepatectomy Group

Abstract Background Repeat hepatectomy and radiofrequency ablation (RFA) are widely used to treat early recurrent hepatocellular carcinoma (RHCC) located in the subcapsular region, but the optimal treatment strategy remains to be controversial. Methods A total of 126 RHCC patients in the subcapsular location after initial radical hepatectomy were included in this study between Dec 2014 and Jan 2018. These patients were divided into the RFA group (46 cases) and the repeat hepatectomy group (80 cases). The primary endpoints include repeat recurrence-free survival (rRFS) and overall survival (OS), and the secondary endpoint was complications. The propensity-score matching (PSM) was conducted to minimize the bias. Complications were evaluated using the Clavien-Dindo classification, and severe complications were defined as classification of complications of ≥grade 3. Results There were no significant differences in the incidence of severe complications were observed between RFA group and repeat hepatectomy group in rRFS and OS both before (1-, 2-, and 3-year rRFS rates were 65.2%, 47.5%, and 33.3% vs 72.5%, 51.2%, and 39.2%, respectively, P = 0.48; 1-, 2-, and 3-year OS rates were 93.5%, 80.2%, and 67.9% vs 93.7%, 75.8%, and 64.2%, respectively, P = 0.92) and after PSM (1-, 2-, and 3-year rRFS rates were 68.6%, 51.0%, and 34.0% vs 71.4%, 42.9%, and 32.3%, respectively, P = 0.78; 1-, 2-, and 3-year OS rates were 94.3%, 82.9%, and 71.4% vs 88.6%, 73.8%, and 59.0%, respectively, P = 0.36). Moreover, no significant differences in the incidence of severe complications were observed between the RFA group and repeat hepatectomy group. Conclusion Both repeat hepatectomy and RFA are shown to be effective and safe for the treatment of RHCC located in the subcapsular region.

Sign in / Sign up

Export Citation Format

Share Document